Sales growth of +7.8% and 20% EBIT margin in Q3e EBITDA '24e-'26e revised down 1.
Luxbright AB (”Luxbright” eller ”Bolaget”) meddelade den 15 oktober att Bolaget lanserar en högprest...
Redeye expects a stable Q2 report from Lagercrantz with muted organic growth yet solid margins.
Redeye provides a brief comment on Freemelt's order from a global orthopedic implant OEM, marking a ...
Redeye lowers its forecasts for Q3 and 2024 somewhat on the back of a slightly softer outlook in Nor...
Redeye comments on Freemelt ahead of its Q3 results, due on 5 November.
We cut '24e-'26e EBITA by 21-4%... ...due to weaker IT consulting market data '25e EV/EBITA of ~7x ...
Minor estimate changes Gross margin improvements set to continue Trading at NTM EV/EBITA of ~10x Wh...
We trim '24e-'26e ARR by 1% on continued macro weakness Still awaiting a return in B2C business mome...
Q3'24 results due 25 October '24e-'26e adj. EBIT revised down 0.
STENOCARE announced on October 14th that the company has updated the sales guidance for 2024, from g...
Efterfrågan har överlag hittills varit stabil, men med en svagare efterfrågan inom de breda industri...
Redeye has a positive view on the news from this morning, announcing that Saniona's collaboration wi...
Leader in children's smartwatches, entering new verticals ~800k subscriptions and 52% EBITA CAGR by ...
Lumi Gruppen announced a trading update today for the school year 2024-25.
Q3e: -1% organic sales growth y-o-y, 7% adj. EBITA margin We decrease '25e-'26e sales by 2% Trading ...
Redeye shares its preview of BONESUPPORT’s Q3 2024 results, due October 24.
Redeye presents its preview of Sedana Medical’s Q3 2024 report, due October 24.
Redeye presents its preview for Devyser’s Q3 2024 report, due on October 30.
Redeye offers a preview of SSH's Q3 results set to be released on October 24.
